Chi Mei Medical Center CMMC - Yongkang branch

Tainan 71004

0 studies enrolling now · 2 studies all time

What they study most

Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements, HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer

Studies at this site

• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements — Stopped early